Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Valion Bio (TIVC) Assets (2021 - 2025)

Valion Bio has reported Assets over the past 5 years, most recently at $31.6 million for Q4 2025.

  • For Q4 2025, Assets rose 1026.01% year-over-year to $31.6 million; the TTM value through Dec 2025 reached $31.6 million, up 1026.01%, while the annual FY2025 figure was $31.6 million, 1026.01% up from the prior year.
  • Assets for Q4 2025 was $31.6 million at Valion Bio, up from $6.2 million in the prior quarter.
  • Over five years, Assets peaked at $31.6 million in Q4 2025 and troughed at $2.8 million in Q4 2024.
  • A 5-year average of $8.1 million and a median of $5.9 million in 2022 define the central range for Assets.
  • Biggest five-year swings in Assets: plummeted 60.93% in 2022 and later surged 1026.01% in 2025.
  • Year by year, Assets stood at $15.0 million in 2021, then plummeted by 60.93% to $5.9 million in 2022, then dropped by 12.22% to $5.2 million in 2023, then plummeted by 45.57% to $2.8 million in 2024, then surged by 1026.01% to $31.6 million in 2025.
  • Business Quant data shows Assets for TIVC at $31.6 million in Q4 2025, $6.2 million in Q3 2025, and $4.5 million in Q2 2025.